[144] Collegium Pharmaceutical, Inc. SEC Filing

Rhea-AI Filing Summary

Collegium Pharmaceutical, Inc. (COLL) filed a Form 144 reporting a proposed sale of 4,861 common shares. The shares are to be sold through Fidelity Brokerage Services LLC on NASDAQ with an aggregate market value of $184,880.87. The company reports 31,502,127 shares outstanding, giving context to the size of this proposed sale relative to the total share base.

The filing shows the shares were acquired via an option granted on 02/05/2020 from the issuer and the transaction lists cash as the form of payment. The filer reports no securities sold in the past three months and makes the required representation that they are not aware of material nonpublic information about the issuer.

Insights

Securities Analyst

TL;DR: Routine insider sale notice for a small block of 4,861 shares; unlikely to be material to valuation.

The Form 144 discloses a proposed sale of 4,861 common shares through Fidelity with an aggregate value of $184,880.87 and lists total outstanding shares of 31,502,127. This is a standard regulatory disclosure enabling a restricted or control person to sell shares under Rule 144. The filing notes acquisition by option (granted 02/05/2020) and payment in cash on the sale date. No prior sales in the past three months were reported. From a market-impact perspective, the disclosed block is small relative to the outstanding float and appears to be a routine liquidity event rather than an indicator of broader holder attrition.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure; the filer affirms absence of undisclosed material information and documents an option-origin sale.

The notice documents that the shares to be sold were acquired from the issuer via an option granted on 02/05/2020 and that the filer represents they possess no undisclosed material adverse information. Such certifications are standard and relevant for governance oversight and insider trading controls. The absence of recent sales in the prior three months simplifies aggregation considerations under Rule 144. This filing serves as a transparent record of an insider liquidity action but does not, on its face, raise governance red flags.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	4861	184880.87	31502127	08/13/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/13/2025	Option Granted - 02/05/2020	Issuer			4861	08/13/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Collegium (COLL) report?

The Form 144 reports a proposed sale of 4,861 common shares through Fidelity with an aggregate market value of $184,880.87 to be sold on NASDAQ.

How many Collegium shares are outstanding according to this filing?

The filing lists 31,502,127 shares outstanding.

How were the shares being sold acquired?

The shares were acquired via an option granted on 02/05/2020 from the issuer, per the filing.

Did the filer report any securities sold in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

What representation does the filer make about material information?

The filer represents they do not know of any material adverse information about the issuer that has not been publicly disclosed.